항염증제 시장 : 시장 인사이트, 경쟁 구도, 시장 예측(2030년)

Anti-Inflammatory Drugs Market By Drug Class (Anti-Inflammatory Biologics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Immune-Selective Anti-Inflammatory Derivative (IMSAID), Corticosteroids, And Others), Indication (Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, And Others), Sales Channel (Prescription And Over The Counter (OTC)), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing burden of chronic pain and inflammation diseases such as migraine, arthritis, ophthalmic diseases, and others and the increasing research & developmental activities concerning to the anti-inflammatory drugs across the globe

The global anti-inflammatory drugs market is estimated to at a CAGR of 5.73% during the forecast period from 2024 to 2030. The demand for anti-inflammatory drugs is primarily being boosted by the increasing prevalence of various chronic diseases such as asthma, arthritis, chronic obstructive pulmonary disease (COPD), and other diseases. Further, the increasing research on anti-tumor necrosis factor (TNF), interleukins, Janus kinase inhibitors, anti-inflammatory biologics, immune selective anti-inflammatory derivatives (ImSAIDs), among others, the rising prevalence of auto-immune diseases, increasing focus on developing biosimilar, and the increasing drugs launches and approval across the globe among others are thereby contributing to the overall growth of the anti-inflammatory drugs market during the forecast period from 2024-2030.

Anti-Inflammatory Drugs Market Dynamics:

The anti-inflammatory drugs market is witnessing a growth in product demand owing to various factors, one of the key factors being the rising burden of chronic pain and inflammation across the globe.

According to the Centre for Disease Control and Prevention (CDC) 2020, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities in the past 3 months. Also, chronic pain and high-impact chronic pain both increase with age and were highest among adults aged 65 and over, in the United States. Moreover, as per the same source, non-Hispanic white adults (23.6%) were more likely to have chronic pain compared with non-Hispanic black (19.3%), Hispanic (13.0%), and non-Hispanic Asian (6.8%) adults, in 2019.

Further, asthma is a chronic lung disease affecting people of all ages. It is caused by inflammation and muscle tightening around the airways, which makes it harder to breathe. For instance, as per the source World Health Organization (WHO) 2023, Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths.

The above source states that the prevalence of chronic pain and inflammatory diseases is increasing across the globe which can be managed or treated using various types of anti-inflammatory drugs such as corticosteroids and NSAIDs.

In addition, key pharmaceutical companies concentrating on creating biosimilar-related anti-inflammatory drugs are expected to expand the market. Also, the leading anti-inflammatory biologics' patents expiring paved the path for biosimilars to enter the market. Due to the rising demand and quicker approval process for biosimilars than for new drugs, several manufacturers have moved their attention to this area. This has grown to be a significant market trend. Adalimumab, infliximab, and etanercept biosimilars are competing against Humira, Remicade, and Enbrel, three biologics with considerable market revenue potential.

The FDA has approved five Humira biosimilars, all of which are anticipated to go on sale in the United States in 2023. While the adalimumab biosimilar is now commercially available in other areas, such as Europe.

Additionally, clinical research has already been started to create biosimilar versions of reference biologics that will soon lose their exclusivity. In the upcoming years, this is projected to increase the demand for anti-inflammatory treatments.

Therefore, the above-mentioned factors are contributing to the growth of the anti-inflammatory drugs market during the forecast period from 2024-2030.

However, side effects associated with drugs, stringent regulatory procedures, and others may restrict the anti-inflammatory drugs market growth.

Anti-Inflammatory Drugs Market Segment Analysis:

Anti-Inflammatory Drugs Market by Drug Class (Anti-Inflammatory Biologics, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Immune-Selective Anti-Inflammatory Derivative (IMSAID), Corticosteroids, and Others), Indication (Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, and Others), Sales Channel (Prescription and Over the Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the indication segment of the anti-inflammatory drugs market, the arthritis category is expected to amass a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of arthritis across the globe. Also, the expanding launches and strategic investments, and other activities by the key players related to the segment will support driving its market during the forecast period.

For instance, as per the Global RA Network 2021, more than 350 million people had arthritis, in 2021, globally. Further, the World Health Organization (WHO), 2021, more than 14 million people had rheumatoid arthritis (RA), in 2021, across the globe. Additionally, according to Healio, 2020, it was estimated that more than 42 million people around the world had gout, in 2020.

Non-steroidal anti-inflammatory medicines (NSAIDs), such as diclofenac, ibuprofen, and naproxen, a type of anti-inflammatory drugs are quite helpful at reducing osteoarthritis pain, but they also carry a risk of adverse effects such as stomach upset, and cardiovascular issues, blood issues, liver damage, and kidney damage. Thus, the above sources clearly state that the prevalence of different types of arthritis is quite high across the globe, ultimately leading to the increased demand for arthritis-managing anti-inflammatory drugs.

Further, the increasing product launches and approvals will also create a positive impact on segmental growth. For instance, in January 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa), a type of anti-inflammatory drugs for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.

Thus, the above-mentioned factors are likely to propel the demand for arthritis-treating anti-inflammatory drugs, thereby contributing to the growth of the anti-inflammatory drugs market during the forecast period from 2024-2030.

North America is expected to dominate the overall Anti-Inflammatory Drugs Market:

Among all the regions, North America is estimated to account for the largest share of the global anti-inflammatory drugs market in the year 2023. This domination is due to the increasing chronic pain and rising adoption of NSAIDs in headaches, migraine, toothaches, menstrual pain, and others, increasing launch and approvals of drugs by market players, established healthcare sector with a large number of renowned players, high investment & demand for more effective and safer drug, high income per capita, rise in patient visits to physicians, and research advancements due to high funding among others will propel the market of anti-inflammatory drugs in North America.

For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) 2021, it was stated that in 2020, about one in four US adults, or about 58.5 million people were diagnosed with arthritis. By the year 2040, an estimated 78.4 million adults aged 18 years and older will be diagnosed with arthritis.

Further, as per the latest study done by Osteoarthritis (OA) Action Alliance, osteoarthritis (OA) is the most common form of arthritis, and affects nearly 32.5 million US adults, in 2020. The data analyzed from the source Arthritis Society Canada, 2021, stated that in 2021, nearly 6 million people were living with arthritis in Canada. The number to rise to 9 million in 2040.

Additionally, as per the Migraine Research Foundation (2023), migraine is a highly prevalent neurological disease, affecting nearly 40 million men, women, and children in the US while most sufferers experience attacks once or twice a month, more than 4 million people have chronic daily migraine, with at least 15 migraine days per month. Thus, the rising prevalence of chronic pain and inflammation-related disorders such as migraine, arthritis, and others will propel the demand for anti-inflammatory drugs during the forecast period.

Furthermore, the increasing activities by the key players in the region will in turn increase the demand for the product during the forecast period. For instance, in December 2021, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® XR (tofacitinib), an anti-inflammatory drug for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Thus, all the above-mentioned factors will lead to an increase in the North America anti-inflammatory drugs market growth during the forecasting period of 2024-2030.

Anti-Inflammatory Drugs Market Key Players:

Some of the key market players operating in the anti-inflammatory drugs market include Amgen Inc., Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Pfizer Inc., Medical Device Business Services, Inc., Novartis AG, GSK plc., F. Hoffmann-La Roche Ltd, AbbVie Inc., AstraZeneca, Merck & Co., Inc., Lilly., Bristol-Myers Squibb Company, Biogen, Aurobindo Pharma, Reckitt Benckiser Group PLC., Dr. Reddy's Laboratories Ltd., Sanofi, Strides Pharma Science Limited, Heron Therapeutics, Inc., and others.

Recent Developmental Activities in the Anti-Inflammatory Drugs Market:

In August 2022, Strides Pharma Global Pte Ltd received approval from the US health regulator for generic naproxen sodium soft gel capsules, used to treat pain or inflammation.

In August 2021, Alkem Labs announced the launch of Ibuprofen and Famotidine tablets in the U.S. after receiving approval from the U.S. FDA.

In November 2020, the Food and Drug Administration (FDA) issued an emergency use authorization for the anti-inflammatory drug baricitinib to treat COVID-19 in combination with anti-viral drug remdesivir.

Key Takeaways from the Anti-Inflammatory Drugs Market Report Study

Market size analysis for current anti-inflammatory drugs market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global anti-inflammatory drugs market.

Various opportunities available for the other competitor in the anti-inflammatory drugs market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current anti-inflammatory drugs market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for anti-inflammatory drugs market growth in the coming future?

Target Audience who can be benefited from this Anti-Inflammatory Drugs Market Report Study

Anti-inflammatory drugs products providers

Research organizations and consulting companies

Anti-inflammatory drugs-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in anti-inflammatory drugs

Various End-users who want to know more about the anti-inflammatory drugs market and the latest technological developments in the anti-inflammatory drugs market.

Frequently Asked Questions for the Anti-Inflammatory Drugs Market:

1. What are anti-inflammatory drugs?

Bone void filler is a medical device, intended to fill bony voids or gaps caused by trauma or surgery that are not intrinsic to the stability of the bony structure.

2. What is the market for global anti-inflammatory drugs?

The global anti-inflammatory drugs market is estimated to at a CAGR of 5.73% during the forecast period from 2024 to 2030.

3. What are the drivers for the global anti-inflammatory drugs market?

The demand for anti-inflammatory drugs is primarily being heightened by the growing burden of chronic pain and inflammation such as arthritis, and migraine, among others, the increasing geriatric population base prone to chronic pain, the emergence of anti-inflammatory biologics, and increasing drugs launches and approvals, among others, thereby contribute to the overall growth of the anti-inflammatory drugs market during the forecast period from 2024-2030.

4. Who are the key players operating in the global anti-inflammatory drugs market?

Some of the key market players operating in the anti-inflammatory drugs market include Amgen Inc., Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Pfizer Inc., Medical Device Business Services, Inc., Novartis AG, GSK plc., F. Hoffmann-La Roche Ltd, AbbVie Inc., AstraZeneca, Merck & Co., Inc., Lilly., Bristol-Myers Squibb Company, Biogen, Aurobindo Pharma, Reckitt Benckiser Group PLC., Dr. Reddy's Laboratories Ltd., Sanofi, Strides Pharma Science Limited, Heron Therapeutics, Inc., and others.

5. Which region has the highest share in the anti-inflammatory drugs market?

North America is expected to dominate the overall anti-inflammatory drugs market during the forecast period from 2024-2030. Factors such as the increasing demand for anti-inflammatory biologics, government support for the launch of biosimilars, significant research investment, increased, presence of favorable regulatory authorities, rising product launch and approvals, and the presence of key players in the region, among others will positively impact the North American anti-inflammatory drugs market.

Table of Contents

1. Anti-Inflammatory Drugs Market Report Introduction

2. Anti-Inflammatory Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Anti-Inflammatory Drugs Market Key Factors Analysis

• 4.1. Anti-Inflammatory Drugs Market Drivers
  • 4.1.1. The growing burden of chronic pain and inflammation
  • 4.1.2. Increasing geriatric population base prone to chronic pain
  • 4.1.3. Rising adoption of anti-inflammatory biologics
• 4.2. Anti-Inflammatory Drugs Market Restraints and Challenges
  • 4.2.1. Side effects associated with drugs
  • 4.2.2. Stringent regulatory procedure
• 4.3. Anti-Inflammatory Drugs Market Opportunities
  • 4.3.1. Availability of a robust product portfolio
  • 4.3.2. Increasing focus on developing biosimilars by key pharmaceutical companies

5. Anti-Inflammatory Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. Anti-Inflammatory Drugs Market Layout

• 6.1. By Drug Class
  • 6.1.1. Anti-Inflammatory Biologics
  • 6.1.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • 6.1.3. Immune-selective anti-inflammatory derivative (ImSAID)
  • 6.1.4. Corticosteroids
  • 6.1.5. Others
• 6.2. By Indication
  • 6.2.1. Arthritis
  • 6.2.2. Asthma
  • 6.2.3. Inflammatory bowel disease (IBD)
  • 6.2.4. Chronic obstructive pulmonary disease (COPD)
  • 6.2.5. Multiple Sclerosis
  • 6.2.6. Others
• 6.3. By Sales Channel
  • 6.3.1. Prescription
  • 6.3.2. Over the Counter (OTC)
• 6.4. By Geography
  • 6.4.1. North America Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.1.1. United States Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.1.2. Canada Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.1.3. Mexico Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
  • 6.4.2. Europe Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.1. France Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.2. Germany Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.3. United Kingdom Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.4. Italy Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.5. Spain Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.6. Rest of Europe Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
  • 6.4.3. Asia-Pacific Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.1. China Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.2. Japan Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.3. India Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.4. Australia Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.5. South Korea Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.6. Rest of the Asia-Pacific Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
  • 6.4.4. Rest of the World (RoW) Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.4.1. Middle East Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.4.2. Africa Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.4.3. South America Anti-Inflammatory Drugs Market Size in USD million (2021-2030)

7. Anti-Inflammatory Drugs Market Company and Product Profiles

• 7.1. Amgen Inc.
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Sun Pharmaceutical Industries Ltd.
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. Johnson & Johnson Services, Inc.
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. Pfizer Inc.
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. Medical Device Business Services, Inc.
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. Novartis AG
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. GSK plc.
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.3. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. F. Hoffmann-La Roche Ltd
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. AbbVie Inc.
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. AstraZeneca
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. Merck & Co., Inc.
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. Lilly.
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. Bristol-Myers Squibb Company
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. Biogen
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Aurobindo Pharma
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy
• 7.16. Reckitt Benckiser Group PLC.
  • 7.16.1. Company Overview
  • 7.16.2. Company Snapshot
  • 7.16.3. Financial Overview
  • 7.16.4. Product Listing
  • 7.16.5. Entropy
• 7.17. Dr. Reddy's Laboratories Ltd.
  • 7.17.1. Company Overview
  • 7.17.2. Company Snapshot
  • 7.17.3. Financial Overview
  • 7.17.4. Product Listing
  • 7.17.5. Entropy
• 7.18. Sanofi
  • 7.18.1. Company Overview
  • 7.18.2. Company Snapshot
  • 7.18.3. Financial Overview
  • 7.18.4. Product Listing
  • 7.18.5. Entropy
• 7.19. Strides Pharma Science Limited
  • 7.19.1. Company Overview
  • 7.19.2. Company Snapshot
  • 7.19.3. Financial Overview
  • 7.19.4. Product Listing
  • 7.19.5. Entropy
• 7.20. Heron Therapeutics, Inc.
  • 7.20.1. Company Overview
  • 7.20.2. Company Snapshot
  • 7.20.3. Financial Overview
  • 7.20.4. Product Listing
  • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us